Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. In a May 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that for Nabriva Therapeutics Plc (NBRV:NASDAQ) , "all eyes [are] on [its] Au...
Streetwise Reports | May 16, 2019 |

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

The highlights of this investment story are outlined in a Zacks Small-Cap Research report. In a Nov. 19 research note, analyst David Bautz reported that Zacks Small-Cap Research initiated coverage on Avivagen Inc. (VIV:TSX.V; CHEXF:OTCMKTS) with a US$2.50 valuation....
Streetwise Reports | November 27, 2019 |

Large US Market Now Open to Livestock Feed Antibiotic Replacement

Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. Antibiotic resistance is a major health threat worldwide and many countries have banned or are banning the use of antibiotics as growth promoters in livestock. The European...
Streetwise Reports | March 12, 2019 |

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...
Streetwise Reports | August 28, 2019 |

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. A small-cap Canadian company, Avivagen Inc. (VIV:TSX.V) , has developed a feed supplement, OxC-beta™ Livestock, wh...
Streetwise Reports | November 18, 2019 |

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company

Technical analyst Clive Maund believes this stock could gain traction soon. Avivagen Inc. (VIV:TSX.V) is an interesting company because it makes farm animal feed that is free of antibiotics, which is becoming a hot topic now that over half of China's swine herd is se...
Streetwise Reports | October 16, 2019 |

From Ice Cream To Toilet Seats: The Most Bizarre Uses For Gold

I t's currency. It's luxury. It's even dessert. But those are only the base uses of gold. This is the stuff of gods, big and small. Since the dawn of civilization it has held sway over spirit and soul and what the ancient Egyptians knew then, everyone still knows now: Gold is...
Joao Peixe | July 23, 2019 |

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results ...
Streetwise Reports | December 30, 2019 |

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. In a March 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Nabriva Therapeutics Plc (NBRV:NASDAQ) has two antibiotics up for approval...
Streetwise Reports | March 21, 2019 |

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. Late yesterday afternoon, biopharmaceutical company Paratek Pharmaceuti...
Streetwise Reports | December 20, 2019 |
1 2 3 4